Misonix, Inc. (NASDAQ:MSON) shares traded up 17.1% during trading on Friday . The stock traded as high as $20.51 and last traded at $19.62, 103,666 shares traded hands during trading. An increase of 136% from the average session volume of 43,956 shares. The stock had previously closed at $16.75.
Several research analysts have commented on the company. Canaccord Genuity reaffirmed a “buy” rating and set a $30.00 price target (up previously from $24.00) on shares of Misonix in a research report on Thursday, August 15th. ValuEngine lowered Misonix from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, BTIG Research reaffirmed a “buy” rating and set a $27.00 price target on shares of Misonix in a research report on Thursday, August 15th. One analyst has rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $28.50.
The firm has a 50-day simple moving average of $18.09 and a 200 day simple moving average of $20.76.
Large investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. acquired a new position in shares of Misonix in the third quarter valued at approximately $37,000. Strs Ohio acquired a new position in shares of Misonix in the second quarter valued at approximately $50,000. JPMorgan Chase & Co. acquired a new position in shares of Misonix in the second quarter valued at approximately $49,000. WealthTrust Axiom LLC acquired a new position in shares of Misonix in the second quarter valued at approximately $208,000. Finally, Wells Fargo & Company MN increased its holdings in shares of Misonix by 6.2% in the second quarter. Wells Fargo & Company MN now owns 12,369 shares of the medical equipment provider’s stock valued at $313,000 after purchasing an additional 724 shares during the period. 27.20% of the stock is currently owned by institutional investors and hedge funds.
About Misonix (NASDAQ:MSON)
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Further Reading: Does the discount rate affect the economy?
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.